The Spine Journal
Volume 10, Issue 2 , Pages 117-128, February 2010

Dose response and efficacy of spinal manipulation for chronic cervicogenic headache: a pilot randomized controlled trial

  • Mitchell Haas, DC

      Affiliations

    • Center for Outcomes Studies, Western States Chiropractic College, 2900 NE 132nd Ave., Portland, OR 97230, USA
    • Corresponding Author InformationCorresponding author. Center for Outcomes Studies, Western States Chiropractic College, 2900 NE 132nd Ave., Portland, OR 97230, USA. Tel.: (503) 251-5728; fax: (503) 251-2832.
  • ,
  • Adele Spegman, PhD, RN

      Affiliations

    • Institute on Nursing Excellence, Geisinger Center for Health Research, 100 N Academy Ave., Danville, PA 17822, USA
  • ,
  • David Peterson, DC

      Affiliations

    • Center for Outcomes Studies, Western States Chiropractic College, 2900 NE 132nd Ave., Portland, OR 97230, USA
  • ,
  • Mikel Aickin, PhD

      Affiliations

    • Family & Community Medicine, University of Arizona, 4840 N Valley View Rd, Tucson, AZ 85718, USA
  • ,
  • Darcy Vavrek, ND

      Affiliations

    • Center for Outcomes Studies, Western States Chiropractic College, 2900 NE 132nd Ave., Portland, OR 97230, USA

Received 12 January 2009; received in revised form 3 June 2009; accepted 11 September 2009. published online 19 October 2009.

Abstract 

Background context

Systematic reviews of randomized controlled trials suggest that spinal manipulative therapy (SMT) is efficacious for care of cervicogenic headache (CGH). The effect of SMT dose on outcomes has not been studied.

Purpose

To compare the efficacy of two doses of SMT and two doses of light massage (LM) for CGH.

Patient sample

Eighty patients with chronic CGH.

Main outcome measures

Modified Von Korff pain and disability scales for CGH and neck pain (minimum clinically important difference=10 on 100-point scale), number of headaches in the last 4 weeks, and medication use. Data were collected every 4 weeks for 24 weeks. The primary outcome was the CGH pain scale.

Methods

Participants were randomized to either 8 or 16 treatment sessions with either SMT or a minimal LM control. Patients were treated once or twice per week for 8 weeks. Adjusted mean differences (AMD) between groups were computed using generalized estimating equations for the longitudinal outcomes over all follow-up time points (profile) and using regression modeling for individual time points with baseline characteristics as covariates and with imputed missing data.

Results

For the CGH pain scale, comparisons of 8 and 16 treatment sessions yielded small dose effects: |AMD|≤5.6. There was an advantage for SMT over the control: AMD=−8.1 (95% confidence interval=−13.3 to −2.8) for the profile, −10.3 (−18.5 to −2.1) at 12 weeks, and −9.8 (−18.7 to −1.0) at 24 weeks. For the higher dose patients, the advantage was greater: AMD=−11.9 (−19.3 to −4.6) for the profile, −14.2 (−25.8 to −2.6) at 12 weeks, and −14.4 (−26.9 to −2.0) at 24 weeks. Patients receiving SMT were also more likely to achieve a 50% improvement in pain scale: adjusted odds ratio=3.6 (1.6 to 8.1) for the profile, 3.1 (0.9 to 9.8) at 12 weeks, and 3.1 (0.9 to 10.3) at 24 weeks. Secondary outcomes showed similar trends favoring SMT. For SMT patients, the mean number of CGH was reduced by half.

Conclusions

Clinically important differences between SMT and a control intervention were observed favoring SMT. Dose effects tended to be small.

Keywords: Cervicogenic headache, Dose response, Spinal manipulation, Chiropractic, Neck pain, Randomized trial

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 FDA device/drug status: not applicable.

 Author disclosures: MH (investigator salary, staff/materials, clinical staff/training, trips/travels, NCCAM/NIH [R21AT002324]); AS (investigator salary, staff/materials, clinical staff/training, NCCAM/NIH [R21AT002324]); DP (investigator salary, NCCAM/NIH [R21AT002324]).

PII: S1529-9430(09)00851-1

doi:10.1016/j.spinee.2009.09.002

The Spine Journal
Volume 10, Issue 2 , Pages 117-128, February 2010